生命层
发表于 2025-3-25 04:25:28
Federico Della Croce,Rosario Scatamacchiae different molecular, antigen, and serologic tests for the diagnosis of COVID-19. Most cases of COVID-19 require only supportive care; however, in patients with increased risks factors for complications and for those with moderate to severe disease, specific therapeutic options that include antivir
显而易见
发表于 2025-3-25 10:35:56
http://reply.papertrans.cn/47/4683/468242/468242_22.png
Ascribe
发表于 2025-3-25 13:12:03
Szymon Dudycz,Mateusz Lewandowski,Jan Marcinkowskiided that dual antiplatelet therapy after DES implantation is continued for >6 months. The benefits of new (everolimus/zotarolimus) vs. old (sirolimus/paclitaxel) generation DES remain elusive and further studies are needed in this regard. In DM patients with multivessel disease, growing evidence is
accomplishment
发表于 2025-3-25 19:32:39
Eduard Eiben,Robert Ganian,Dušan Knop,Sebastian Ordyniak,Michał Pilipczuk,Marcin Wrochna metformin and GLP-1 agonists) may reduce stroke risk whereas some others (sulfonylureas) are associated with increased incidence and worse prognosis. Warfarin has generally been the anticoagulant of choice for patients at high risk for cardioembolic stroke and low risk of hemorrhagic complications.
Immortal
发表于 2025-3-25 22:55:09
Elisabeth Gaar,Franz Rendl metformin and GLP-1 agonists) may reduce stroke risk whereas some others (sulfonylureas) are associated with increased incidence and worse prognosis. Warfarin has generally been the anticoagulant of choice for patients at high risk for cardioembolic stroke and low risk of hemorrhagic complications.
Fallibility
发表于 2025-3-26 03:26:14
Lukas Graf,Tobias Harksided that dual antiplatelet therapy after DES implantation is continued for >6 months. The benefits of new (everolimus/zotarolimus) vs. old (sirolimus/paclitaxel) generation DES remain elusive and further studies are needed in this regard. In DM patients with multivessel disease, growing evidence is
压迫
发表于 2025-3-26 08:23:01
http://reply.papertrans.cn/47/4683/468242/468242_27.png
Mere仅仅
发表于 2025-3-26 09:07:30
Robert Hildebrand,Matthias Köppe,Yuan Zhouf the same receptor. Fibrates and more recently Omega-3 Fatty Acids are known to activate PPAR-α. Theoretically, PPAR synthetic agonists could have vascular benefits via lowering glucose, raising HDL and decreasing inflammation. Synthetic ligands of PPAR-γ have been shown to decrease surrogate marke
correspondent
发表于 2025-3-26 13:55:54
th a higher number of affected subjects are located in the region (Brazil and Mexico). Prevalence of the disease is close to 10 % in Latin American countries. Type 2 diabetes explains more than 90 % of cases. Peculiar features of type 2 diabetes in mestizo populations have been identified (early ons
宏伟
发表于 2025-3-26 17:39:47
Ahmad Abdi,Gérard Cornuéjols,Dabeen Leely, the prevalence of type 2 diabetes (T2D) in the MENA region is estimated at 9.7 %...: To describe the epidemiology, principal causes, associated risk factors, cultural aspects, and challenges that contribute to the rapid rise in T2D in MENA...: Review of papers in PubMed and relevant gray literat